The diagnostic value of prostate health index combined with soluble e-cadherin for prostate cancer

TL;DR

This study shows that combining the prostate health index and soluble E-cadherin improves accuracy in detecting prostate cancer compared to using either alone.

Contribution

The novel contribution is demonstrating that combining PHI and sE-cadherin improves diagnostic accuracy for prostate cancer.

Findings

sE-cadherin, tPSA, p2PSA, and PHI levels were significantly higher in prostate cancer patients compared to benign cases.

The combination of sE-cadherin and PHI achieved a higher AUC (0.792) than either marker alone.

Higher levels of the combined markers correlated with advanced disease stages, metastasis, and higher Gleason scores.

Abstract

To assess the diagnostic value of combining prostate health index (PHI) and soluble epithelial cadherin (sE-cadherin) in prostate cancer (PCa) detection.

This study included 250 benign prostatic hyperplasia (BPH) and 250 PCa patients (2020–2024). PCa patients were categorized by disease stage (I-II:115; III-IV:135), bone metastasis (non-metastatic:171; metastatic:79), and Gleason score (≤8:136; >8:114). Serum sE-cadherin (ELISA), tPSA, fPSA, and p2PSA (chemiluminescence) were measured; PHI was calculated. ROC curves evaluated diagnostic performance.

sE-cadherin, tPSA, p2PSA, and PHI levels were significantly higher in PCa vs. BPH (P<0.05), with further elevations in advanced stages, metastatic cases, and Gleason >8 (P<0.05). ROC analysis demonstrated AUCs of 0.719 (sE-cadherin), 0.761 (PHI), and 0.792 (combined), indicating superior diagnostic accuracy for the combination.

Combining sE-cadherin and PHI enhances PCa detection accuracy, correlating with disease severity, metastasis, and aggressiveness.

Figures